BioCentury
ARTICLE | Clinical News

Dexmecamylamine: Development discontinued

August 4, 2014 7:00 AM UTC

Targacept discontinued development of TC-5214 to treat OAB after top-line data from a double-blind, U.S. Phase IIb trial in 768 patients with OAB “were not compelling enough to justify the compound’s continued development.” Twice-daily 2 mg oral TC-5214 met the co-primary endpoint of reducing micturition frequency per 24 hours from baseline to week 12 vs. placebo (p=0.033), but missed the co-primary endpoint of reducing urinary incontinence episodes per 24 hours from baseline to week 12 vs. placebo (p=0.379). Patients received placebo or twice-daily 0.5, 1 or 2 mg oral TC-5214 for 12 weeks. The company said TC-5214 led to dose-dependent efficacy on several endpoints, but did not disclose data for the 0.5 and 1 mg doses of TC-5214. TC-5214 was generally well tolerated. ...